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<< ABSTRACT >> [[currently 348 of 350 words permitted]] 
 
IMPORTANCE Some cigarette smokers may not be ready to quit immediately but may be 
willing to reduce cigarette consumption with the goal of quitting.  
 
OBJECTIVE To determine efficacy and safety of varenicline for increasing smoking abstinence 
rates through smoking reduction. 
 
DESIGN, SETTING, AND PARTICIPANTS Randomized, blinded, placebo-controlled, 
multinational clinical trial with a 24-week treatment period and 28-week follow-up conducted 
between July 2011 and July 2013 at 61 centers in 10 countries. 1510 cigarette smokers not 
willing or able to quit smoking within the next month but willing to reduce smoking and make a 
quit attempt within the next 3 months recruited through advertising. 
 
INTERVENTIONS Twenty-four weeks of varenicline titrated to 1 mg twice daily or placebo with 
reduction target of ≥ 50% in number of cigarettes smoked by 4 weeks and ≥ 75% by 8 weeks 
and a quit attempt by 12 weeks. 
 
MAIN OUTCOME MEASURES Primary efficacy endpoint was carbon monoxide (CO)-
confirmed self-reported abstinence during weeks 15-24. Secondary outcomes were CO-
confirmed self-reported abstinence rate for weeks 21-24 and weeks 21-52. 
 
RESULTS The varenicline group (N = 760) had significantly higher continuous abstinence rates 
during weeks 15-24 versus placebo (N = 750) (32.1% vs 6.9%; risk difference (RD) 25.2%; 95% 
CI 21.4%, 29.0%; relative risk (RR) = 4.6; 95% CI 3.5, 6.1). The varenicline group had 
significantly higher continuous abstinence rates versus placebo during weeks 21-24 (37.8% vs 
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12.5%; RD 25.2%; 95 CI 21.1%, 29.4%; RR 3.0; 95% CI 2.4, 3.7) and weeks 21-52 (27.0% vs 
9.9%; RD 17.1%; 95% CI 13.3%, 20.9%; RR 2.7; 95% CI 2.1, 3.5). Serious adverse events 
occurred in 3.7% and 2.2% of the varenicline and placebo groups, respectively (P = 0.07). 
 
CONCLUSIONS AND RELEVANCE Among cigarette smokers not willing or able to quit within 
the next month but willing to reduce cigarette consumption and make a quit attempt in the next 
3 months, use of varenicline for 24 weeks compared with placebo significantly increased 
smoking cessation rates through 6 months of follow up. Varenicline offers a treatment option for 
smokers whose needs are not addressed by clinical guidelines recommending abrupt smoking 
cessation. 
 
Trial Registration: www.clinicaltrials.gov (NCT01370356): 
https://clinicaltrials.gov/ct2/results?term=NCT01370356&Search=Search  
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INTRODUCTION 
 
Forty percent of cigarette smokers make an average of two quit attempts annually.1 In a 
telephone survey of 1000 current daily cigarette smokers, 44% reported a preference to quit 
through reduction in the number of cigarettes smoked, and 68% would consider using a 
medication to facilitate smoking reduction.2 However, the U.S. Clinical Practice Guidelines 
recommend that smokers quit abruptly3 even though only 8% of smokers report being ready to 
quit in the next month.4 Developing effective interventions to achieve tobacco abstinence 
through gradual reduction could engage more smokers in quitting.5-7  
Among cigarette smokers not ready to quit, tobacco reduction incorporating nicotine 
replacement therapy and behavioral interventions decrease cigarettes smoked and increase 
future smoking abstinence.6,7 Population-based studies suggest that quitting gradually may be 
less successful than quitting abruptly.8 However, a systematic review comparing both 
approaches suggests that reducing cigarettes before the quit date and quitting abruptly without 
prior reduction yields comparable quit rates.9  
Almost all prior studies of pharmacotherapy-aided reduction have examined nicotine 
replacement therapies. Varenicline is a partial agonist binding with high affinity and selectivity at 
4β2 neuronal nicotinic acetylcholine receptors.
10 Varenicline significantly increases smoking 
abstinence rates among smokers seeking treatment and quitting abruptly.11,12 Among smokers 
not trying to stop, varenicline significantly reduces cigarette consumption13 and may increase 
quit attempts.14  
Varenicline may be an effective intervention for smokers who are not willing or able to 
make an immediate quit attempt but who would be willing to reduce their smoking in preparation 
for a quit attempt in the future (ie, a “reduce-to-quit” approach). A prior reduce-to-quit study of 
varenicline was small, provided only 8 weeks of varenicline, and obtained equivocal results.14 
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We conducted a large, randomized, placebo-controlled clinical trial providing varenicline for 6 
months to evaluate a “reduce-to-quit” approach.  
 
METHODS 
 
Study Design 
A phase 4, randomized, double-blinded, placebo-controlled trial was conducted at 61 centers in 
10 countries (Australia, Canada, Czech Republic, Egypt, Germany, Japan, Mexico, Taiwan, 
U.K., and U.S.) between July 2011 and July 2013. Study sites included clinical trial centers, 
academic centers, and outpatient clinics. Study site training was provided at an investigator 
meeting with training materials maintained and accessible through a shared website. The study 
consisted of a 24-week treatment period followed by a 28-week non-treatment follow-up phase. 
The first 12 weeks of treatment were the reduction phase and the next 12 weeks were the 
abstinence phase. Written consent forms and study procedures were approved by the 
institutional review boards or ethics committees of participating institutions. Participants were 
recruited through advertising. Recruitment advertisements included the following language: 
“Want to quit smoking but prefer to cut down first?” and “Are you ready to quit but prefer to do it 
gradually?” and “Want to quit smoking, but hate the idea of going cold turkey?” Enrollment 
ended when recruitment goals were achieved. 
 
Screening and Eligibility Criteria 
Eligible participants were ≥ 18 years of age, smoked an average of ≥ 10 cigarettes/day with no 
continuous abstinence period > 3 months in the past year, had an exhaled carbon monoxide 
(CO) > 10 parts per million (ppm), and were not willing or able to quit smoking within the next 
month but were willing to reduce their smoking and make a quit attempt within the next 
3 months.  
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Exclusion criteria included: a history of suicide attempt or suicidal behavior in previous 2 
years as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)15 and the Suicide 
Behavior Questionnaire-Revised (SBQ-R)16; physician-assessed severe major depressive or 
anxiety disorder (lifetime or current) or unstable (ie, medication dose change or exacerbations 
last 6 months); lifetime diagnosis of psychosis, panic disorder, posttraumatic stress disorder, or 
schizophrenia; alcohol or substance abuse in the last 12 months; a diagnosis of severe chronic 
obstructive pulmonary disease; clinically significant cardiovascular or cerebrovascular disease 
in the previous 2 months; taking more than a limited number of doses of varenicline previously; 
and self-reported inability to abstain from non-cigarette tobacco products, marijuana, or smoking 
cessation aids (including electronic cigarettes). Females were excluded if pregnant, lactating, or 
likely to become pregnant and unwilling to use contraception. 
 
Study Procedures 
Participants were randomized to varenicline or placebo for 24 weeks of treatment in a 1:1 ratio 
using a computer-generated block randomization schedule within site. Investigators obtained 
participant identification numbers and treatment group assignments through a web-based or 
telephone call-in drug management system. Participants, investigators, and research personnel 
were blinded to randomization until after the database was locked.  
Race/ethnicity was self-reported. At each clinic visit and telephone contact, information 
was collected on cigarette or other nicotine product use. Exhaled CO measurements were 
obtained at all clinic visits. Tobacco dependence was assessed with the Fagerström Test for 
Cigarette Dependence (FTCD).17 Study design is shown in the eFigure. 
Adverse events (AEs) and Food and Drug Administration defined serious AEs (SAEs: 
AEs resulting in death, hospitalization, or other important medical events) were collected during 
study visits during the treatment phase and up to 1 month after last treatment dose. A semi-
structured interview solicited information about psychiatric AEs. Suicidal ideation and behavior 
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were assessed using the C-SSRS at baseline and all study visits. Participants completed the 
Patient Health Questionnaire (PHQ)-918 to assess the frequency and severity of potential 
depression-related events every other week during the treatment phase and at clinic visits 
during the follow-up phase. 
 
Interventions 
Participants were asked to reduce baseline smoking rate by ≥ 50% by week 4 with further 
reduction to 75% from baseline by week 8 with the goal of quitting by week 12. Counseling 
training was provided at the investigator meeting. Smoking cessation counseling was provided 
consistent with recommendations of the “Treating Tobacco Use and Dependence” clinical 
practice guideline.3 Participants received the “Clearing the Air – Quit Smoking Today” booklet. 
Advice on reduction techniques was provided such as systematically increasing the amount of 
time between cigarettes and rank-ordering cigarettes from easiest to hardest to give up and 
giving up the easiest to the hardest.14 Counseling was tailored to the participant’s needs during 
the reduction, abstinence, and posttreatment phases. Counsellors were urged to be consistent 
and brief, to focus on problem solving (eg, what triggers the urge to smoke) and skills training 
(eg, practical actions to avoid smoking), and to highlight successes not failures. Individual 
counseling lasted ≤ 10 minutes per visit during 18 clinic and 10 telephone visits. The last 
cigarette was to be smoked prior to midnight on the day prior to the week 12 visit. Participants 
could reduce their smoking faster and could make a quit attempt prior to week 12. Participants 
who had not reduced or made a quit attempt by week 12 were encouraged to continue 
medications and visits and make quit attempts, and participants who relapsed after week 12 
were encouraged to make new quit attempts. After the 24-week treatment phase (ie, 12 weeks 
of reduction and 12 weeks post quit attempt) participants were followed through to week 52 (28-
week non-treatment follow-up phase). 
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Participants started with a recommended varenicline (or matching placebo) dosage of 
0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the 
maintenance dose of 1 mg twice daily.  
 
Study Endpoints 
The primary efficacy endpoint was the CO-confirmed continuous smoking abstinence rate 
(CAR) during the last 10 weeks of treatment (ie, weeks 15 through 24). A participant was 
considered abstinent from tobacco if he or she self-reported tobacco abstinence throughout the 
period and had an exhaled CO ≤ 10 ppm at each visit. In the case of a missing visit, participants 
were considered abstinent if they were abstinent at the next nonmissed visit and also reported 
not smoking during the missed visit. A missing CO did not disqualify a participant from meeting 
the endpoint if they self-reported not smoking Secondary efficacy endpoints were the CARs 
during weeks 21 through 24 and during weeks 21 through 52. We also calculated the non-
prespecified endpoint of the CAR for weeks 15 to 52. 
 
Statistics 
The efficacy analysis was based on the intent-to-treat population (all randomized participants). 
Drop-outs were treated as smokers.  A sample size of 1404 randomized participants in a 1:1 
ratio (702 in each group) was estimated to provide ≥ 90% power to detect a difference between 
varenicline and placebo of 10.3% in the primary endpoint of CAR during weeks 15 to 24, 
assuming a CAR of 17.2% for varenicline and 6.9% for placebo using a 2-group continuity-
corrected 2-sided Chi-Square test at the 0.05 significance level.9,19,20 
A logistic regression model included treatment effect as the explanatory variable and 
investigative center as covariate. In addition, an expanded logistic regression model including 
the treatment-by-center interaction was used to test for the interaction effect. However, as 
prespecified in the statistical analysis plan, the inferences were based solely on the 
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predesignated logistic regression model including only the main effects of treatment and center, 
regardless of the significance of the treatment by center interaction (tested at the 0.05 
significance level). Relative Risks (RRs) and Risk Differences (RDs) calculated using Proc Freq 
with option RELRISK and RISKDIFF, respectively, are reported for efficacy endpoints. We 
conducted a sensitivity analysis for the primary endpoint in which participants who were missing 
a CO during weeks 15-24 were classified as smokers. 
To preserve the type-I family-wise error rate of 0.05, a fixed-sequence procedure was 
used. The treatment comparison was performed first for weeks 15 through 24, then for weeks 
21 through 24, and then for weeks 21 to 52. A post-hoc analysis was conducted in the same 
manner for the endpoint of the CAR for weeks 15 to 52. Each test used a 0.05 level of 
significance. We used SAS Version 9.2 for statistical analyses. 
Adverse events were coded using the Medical Dictionary for Regulatory Activities 
(MedDRA; version 16.1).21 Adverse events occurring during treatment and up to 30 days after 
last dose of study drug are reported. All safety analyses included all randomized participants 
who received any dose of study medication. Our study was not powered to detect significant 
differences in AEs between groups. 
 
RESULTS 
 
Enrollment and Follow-Up 
Of 1747 potentially-eligible participants screened, 1510 (86%) were randomly assigned to 
varenicline (N = 760) and placebo (N = 750). Overall study completion was defined as 
completion of the week 52 visit and was 73.6% (559/760 participants) in the varenicline group 
and 68.7% (516/750 participants) in the placebo group (Figure 1). Participants assigned to 
study groups were similar in demographic and smoking characteristics at baseline (Table 1). 
Participants who discontinued treatment were encouraged to remain in the study. 
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Smoking Abstinence 
 The varenicline group (N = 760) had significantly higher continuous abstinence rates during 
weeks 15-24 versus placebo (N = 750) (32.1% vs 6.9%; risk difference (RD) = 25.2%; 95% CI 
21.4%, 29.0%; relative risk (RR) = 4.6; 95% CI 3.5, 6.1) (Table 2). The varenicline group had 
significantly higher continuous abstinence rates versus placebo during weeks 21-24 (37.8% vs 
12.5%; RD = 25.2%; 95% CI 21.1%, 29.4%; RR = 3.0; 95% CI 2.4, 3.7) and weeks 21-52 
(27.0% vs 9.9%; RD = 17.1%; 95% CI 13.3%, 20.9%; RR =  2.7; 95% CI 2.1, 3.5). No significant 
treatment-by-center interaction for the primary endpoint was observed in the logistic regression 
model. 
Among the 244 varenicline participants who were counted as abstinent for the primary 
endpoint, there were 25 with at least one missing CO measurement (including those with 
missing visits) during weeks 15-24; among the 52 placebo participants who met the primary 
endpoint there were 4 such participants with missing CO. We conducted a sensitivity analysis 
with participants who were missing a CO being classified as smokers for the week 15-24 
continuous abstinence rate (varenicline 219 [28.8%] vs. placebo 48 [6.4%]). The relative risk for 
this analysis was 4.5 (95% CI: 3.4, 6.1). This value approximates the value we observed using 
the pre-specified imputation (RR = 4.6; 95% CI 3.5, 6.1).Among participants meeting the 
primary endpoint (abstinent during weeks 15-24), the median time from baseline to the 
beginning of the continuous abstinence period was 50 days for varenicline and 85 days for 
placebo (P < .0001). The varenicline group also had a significantly higher 7-day point 
prevalence smoking abstinence rate compared with placebo at weeks 12, 24, and 52 (Figure 
2). Varenicline significantly increased the 4-week point prevalence smoking abstinence rate 
compared with placebo at week 52 (32.8% vs 17.3%; RD = 15.4%; 95% CI 11.1%, 19.7%; RR = 
1.9; 95% CI 1.6, 2.3)   
Smoking Reduction (Weeks 1 to 12) 
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At week 4, 47.1% (358/760) of varenicline-treated participants reduced the number of cigarettes 
(i.e., average number of cigarettes during days on which smoking occurred over the last week) 
smoked per day compared with baseline by ≥ 50% or abstained completely compared with 
31.1% (233/750) of participants in placebo (RD = 16.0%; 95% CI 11.2%, 20.9%; RR = 1.5; 95% 
CI 1.3, 1.7). After 8 weeks, 26.3% (200/760) of the varenicline group reduced smoking by ≥ 75% 
from baseline or abstained compared with 15.1% (113/750) of placebo (RD = 11.3; 95% CI 
7.2%, 15.3%; RR = 1.8; 95% CI 1.4, 2.2). 
 
Safety  
The percentage of participants with AEs was higher in the varenicline group than in the placebo 
group (618/751 [82.3%] vs 538/742 [72.5%] participants). AEs with the greatest risk difference 
between varenicline and placebo (> 2%) were nausea, abnormal dreams, insomnia, 
constipation, vomiting, and weight gain (Table 3). AE incidence resulting in permanent 
treatment discontinuation was not significantly different between the 2 groups (63/751 [8.4%] vs 
52/742 [7.0%] participants; P = .27). Percentages of participants with SAEs were not 
significantly different between varenicline and placebo (28/751 [3.7%] vs 16/742 [2.2%] 
participants; P = .07). During treatment and ≤ 30 days after the last dose, suicidal ideation or 
behavior was recorded on the C-SSRS in 6/751 (0.8%) varenicline participants and 10/742 
(1.4%) placebo participants. Any increases in PHQ-9 depression scores from baseline to any 
time point during the post-baseline phase occurred in 169/751 (22.5%) participants treated with 
varenicline compared with 145/742 (19.5%) of placebo participants (P = .16).  
 
DISCUSSION 
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Among cigarette smokers not willing or able to quit smoking in the next month but willing to 
reduce with the goal of quitting in the next 3 months, varenicline produced a statistically and 
clinically significant increase in the CARs at the end of treatment and after 28 weeks 
posttreatment. Varenicline produced greater smoking reduction than placebo prior to quitting. 
Varenicline was not associated with significant increases in treatment discontinuations due to 
AEs. 
Smokers enrolled in the current study were not ready to quit in the next month, and 
overall smoking abstinence rates would have been expected to be low. Although they were low 
in the placebo group, varenicline increased the rates of achieving abstinence such that the 
absolute abstinence rates were similar to those observed in studies of varenicline in smokers 
motivated to quit after one week of treatment.11,12  
The mechanism of varenicline action as an aid to gradual cessation could relate to a 
reduction in cigarette craving or blockade of the reinforcing action of nicotine through partial 
agonist activity at the nicotinic acetylcholine receptors.10 Ancillary effects from varenicline may 
exist with respect to confidence in ability to quit. However, this should have been controlled 
through study blinding and any effect via this route is likely to be small given limited evidence 
that confidence plays a causal role in sustaining quitting attempts.22  
Adverse events caused by varenicline were similar to previous observations. In the 
present study, varenicline was associated with an increased rate of constipation and weight 
gain. However, both are established effects of smoking cessation,23,24 and it is possible that the 
greater incidence of abstinence with varenicline and not the direct effect of varenicline was the 
cause. The incidence of bronchitis was lower in those treated with varenicline, an effect which is 
possibly mediated by an increased rate of smoking cessation.25 Varenicline did not increase the 
risk of suicidal ideation or behavior or other psychiatric AEs. 
Major strengths of this study include the randomized design, large sample size, large 
treatment effect, and convergent validity of the findings across multiple outcomes and 
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measures. One limitation of this study relates to the exclusion of potential participants if they 
had severe psychiatric, pulmonary, cardiovascular, or cerebrovascular disease. As a result, the 
generalizability of this treatment approach to a broader population of smokers who need to quit 
smoking but may want to achieve it through reduction is unknown. In addition, participants in the 
current study were provided with significant support with counseling from trained staff occurring 
during 18 clinic and 10 telephone visits. Because of this, the observed abstinence rates with 
varenicline in actual clinical practice might be expected to be less than that observed in the 
current trial. We did not test whether varenicline would be more effective for reduce-to-quit than 
other tobacco treatments such as nicotine replacement therapy. 
Uncertainty remains as to the prevalence of smokers in the general population who meet 
the definition of smokers enrolled in this study. In a cross-sectional study collecting data via 
telephone or face-to-face interview with daily smokers responding to the Current Population 
Survey, the prevalence of contemplators (i.e., interested in quitting smoking in next 6 months 
but not in the next 30 days) was 33.2%.26 We were not attempting to fit smokers into a specific 
stage of change based upon the transtheoretical model.27 Instead, our approach aimed to 
reduce barriers to engaging in the quitting process by allowing and facilitating smoking reduction 
in a precessation phase.28 Our sample most closely resembles the 33% of smokers who want to 
quit sometime between 1 and 6 months in the future. The approach used in this study would be 
expected to be of interest to 14 million of the 42 million current smokers. 
 
The U.S. Public Health Service3 and other guidelines recommend smokers set a quit 
date in the near future and quit abruptly. However, many smokers may be unwilling to commit to 
a quit date at a clinic visit. Since most clinicians are likely to see smokers at times when a quit 
date in the next month is not planned, the current study indicates that prescription of varenicline 
with a recommendation to reduce the number of cigarettes smoked per day with the eventual 
goal of quitting could be a useful therapeutic option for this population of smokers. The 
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approach of reduction with the goal of quitting increases the options for a clinician caring for a 
smoker.   
 
Conclusion 
This study provides evidence that varenicline can increase smoking abstinence rates among 
smokers electing to reduce their smoking rate over 3 months while working toward the goal of 
smoking abstinence. This approach could engage a substantial number of additional smokers in 
the quitting process. Treatment with varenicline in this population using this approach is 
effective and safe.   
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FIGURE LEGENDS 
 
Figure 1. CONSORT Diagram 
aParticipants not randomized to study treatment due to reasons classified by the investigators as 
“other” included reasons such as: did not attend randomization visit; unable to commit to 
attending study visits; change in work schedule; change in concomitant medications; change in 
personal circumstances; and unavailability of urine drug screening kits. bTreatment phase was 
weeks 1 through 24. Includes 9 varenicline participants and 7 placebo participants who 
withdrew from the study before receiving study medication counted under the respective 
category for reasons of withdrawal. Note that one placebo participant stayed in the study 
although did not take any study medication, also see d. Discontinuations from study due to 
reasons classified by the investigators as “other” included reasons such as: new job or change 
in work schedule; moved out of area; change in personal or family circumstances; and unwilling 
or unable to attend visits. cInsufficient clinical response was a prepopulated option chosen by 
the investigators on the case report forms. dIncludes 1 placebo participant who did not receive 
any study medication but completed the study. ePost-treatment follow-up phase was weeks 25 
through 52. Discontinuations from study due to reasons classified by the investigators as “other” 
included reasons such as: new job or change in work schedule; moved out of area; change in 
personal or family circumstances; and unwilling or unable to attend visits. 
  
Figure 2. 7-Day Point Prevalence Smoking Abstinence and 95% Confidence Intervals 
Week 12 RD = 24.5%; 95% CI 20.8%, 28.3%; RR = 4.7; 95% CI 3.5, 6.2. Week 24 RD = 25.7%; 
95% CI 21.2%, 30.1%; RR = 2.5; 95% CI 2.1, 3.0. Week 52 RD = 15.8%; 95% CI 11.5%, 
20.2%); RR = 1.9, 95% CI 1.6, 2.2. 
Abbreviations: RD, risk difference; RR, relative risk; CIs, confidence intervals; N, all randomized 
participants. 
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Table 1. Participant Characteristics  
 
Varenicline 
(N = 760) 
Placebo 
(N = 750) 
Demographic Characteristics 
Sex, n (%)   
Male 
Female 
425 (55.9) 
335 (44.1) 
426 (56.8) 
324 (43.2) 
Age, years   
Mean (SD) 44.7 (11.8) 44.4 (12.0) 
Range  19-79  18-78 
Race, n (%)   
White 476 (62.6) 463 (61.7) 
Black 36 (4.7) 47 (6.3) 
Asian 175 (23.0) 177 (23.6) 
Other 73 (9.6) 63 (8.4) 
Smoking Characteristics 
Fagerström Test for Cigarette Dependence
a
, mean (SD) 5.5 (2.1) 5.6 (2.0) 
Age started smoking, years, mean (SD) 17.3 (4.3) 17.3 (4.4) 
Number of cigarettes per day in past month, mean (SD) 20.6 (8.5) 20.8 (8.2) 
Longest period of abstinence, days 
 
Since started smokingMedian (25
th
, 75
th
 percentile) 
Mean 
In past year 
Median (25
th
, 75
th
 percentile) 
Mean 
30 (3, 240)272 
 
0 (0, 1) 
4 
21 (2, 180)206 
 
0 (0, 0) 
3 
Number of serious quit attempts by any method, n (%)  
Since started smoking  
None 130 (17.1) 159 (21.2) 
One 191 (25.1) 188 (25.1) 
Two 139 (18.3) 110 (14.7) 
Three or more 300 (39.5) 293 (39.1) 
a
Fagerström Test for Cigarette Dependence measures degree of cigarette dependence with scores 
ranging from 0 to 10 with higher scores indicating a higher degree of dependence.
17
 
Abbreviations: N = all randomized participants; n = number of participants with the given characteristic; 
SD = standard deviation. 
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Table 2. Continuous Abstinence for Weeks 15–24, 21–24, 21–52, and 15–52 
  
Continuous 
Abstinence  
n (%) 
Risk Difference, % 
(95% CI)  
versus placebo 
Relative Risk 
 (95% CI)  
versus placebo 
Primary Endpoint 
Weeks 15–24  Varenicline (N = 760) 244 (32.1) 25.2 
(21.4, 29.0) 
4.6  
(3.5, 6.1) Placebo (N = 750) 52 (6.9) 
Secondary Endpoints 
Weeks 21–24  Varenicline (N = 760) 287 (37.8) 25.2 
(21.1, 29.4) 
3.0 
(2.4, 3.7) Placebo (N = 750) 94 (12.5) 
Weeks 21–52  Varenicline (N = 760) 205 (27.0) 17.1 
(13.3, 20.9) 
2.7 
(2.1, 3.5) Placebo (N = 750) 74 (9.9) 
Post-hoc Endpoint 
Weeks 15–52  
Varenicline (N = 760) 182 (24.0) 
18.0 
(14.5, 21.4) 4.0 
(2.9, 5.4) 
Placebo (N = 750) 45 (6.0)  
Abbreviations: N = all randomized participants; n = number of participants continuously abstinent 
during time period; CI = confidence interval 
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Table 3. Adverse Events Occurring During Treatment Plus 30 Days in ≥ 2% of 
Participants who Received ≥ 1 Dose of Study Drug in Either Treatment Group 
 
Adverse Events 
MedDRA Preferred Term 
Varenicline 
(N = 751) 
n (%) 
Placebo 
(N = 742) 
n (%) 
Risk Difference (%) 
(varenicline vs. 
placebo) 
95% 
Confidence 
Interval (%) 
Nausea 209 (27.8) 67 (9.0) 18.80 14.99, 22.61 
Nasopharyngitis 98 (13.0) 89 (12.0) 1.05 -2.30, 4.41 
Abnormal dreams 86 (11.5) 43 (5.8) 5.66 2.83, 8.49 
Insomnia 80 (10.7) 51 (6.9) 3.78 0.92, 6.64 
Upper respiratory tract infection 63 (8.4) 63 (8.5) -0.10 -2.92, 2.72 
Headache 62 (8.3) 54 (7.3) 0.98 -1.74, 3.69 
Anxiety 52 (6.9) 65 (8.8) -1.84 -4.56, 0.89 
Fatigue 46 (6.1) 34 (4.6) 1.54 -0.74, 3.82 
Irritability 39 (5.2) 30 (4.0) 1.15 -0.98, 3.28 
Constipation 38 (5.1) 13 (1.8) 3.31 1.48, 5.14 
Increased appetite 37 (4.9) 30 (4.0) 0.88 -1.22, 2.98 
Sleep disorder 37 (4.9) 29 (3.9) 1.02 -1.06, 3.10 
Dizziness 32 (4.3) 27 (3.6) 0.62 -1.35, 2.60 
Vomiting 31 (4.1) 13 (1.8) 2.38 0.67, 4.08 
Back pain 28 (3.7) 29 (3.9) -0.18 -2.12, 1.76 
Weight increased 28 (3.7) 12 (1.6) 2.11 0.48, 3.74 
Diarrhea 27 (3.6) 23 (3.1) 0.50 -1.33, 2.32 
Depressed mood 26 (3.5) 27 (3.6) -0.18 -2.05, 1.70 
Depression 25 (3.3) 35 (4.7) -1.39 -3.38, 0.61 
Decreased appetite 20 (2.7) 19 (2.6) 0.10 -1.52, 1.72 
Agitation 20 (2.7) 14 (1.9) 0.78 -0.74, 2.29 
Dyspepsia 19 (2.5) 9 (1.2) 1.32 -0.05, 2.69 
Abdominal pain upper 18 (2.4) 7 (0.9) 1.45 0.16, 2.75 
Middle insomnia 17 (2.3) 11 (1.5) 0.78 -0.59, 2.16 
Flatulence 17 (2.3) 6 (0.8) 1.46 0.21, 2.70 
Influenza 16 (2.1) 12 (1.6) 0.51 -0.86, 1.89 
Dry mouth 16 (2.1) 11 (1.5) 0.65 -0.70, 2.00 
Abdominal distention 16 (2.1) 8 (1.1) 1.05 -0.22, 2.32 
Somnolence 15 (2.0) 10 (1.3) 0.65 -0.65, 1.95 
Initial insomnia 15 (2.0) 9 (1.2) 0.78 -0.49, 2.06 
Cough 14 (1.9) 23 (3.1) -1.24 -2.81, 0.34 
Disturbance in attention 13 (1.7) 17 (2.3) -0.56 -1.98, 0.86 
Sinusitis 12 (1.6) 16 (2.2) -0.56 -1.94, 0.82 
Bronchitis 10 (1.3) 23 (3.1) -1.77 -3.26, -0.28 
Abbreviations: MedDRA = Medical Dictionary for Regulatory Activities; N = number of participants who 
received 1 dose of study drug, including partial doses; n = number of participants reporting AEs. 
All participants had been randomized and had received at least 1 dose (including partial doses) of study 
drug; and includes all participants who had experienced an adverse event from the date of first dose of 
study drug and up to 30 days after the last dose of study drug. Adverse events were recorded in the 
clinical report form (volunteered and observed adverse events) and, in addition, neuropsychiatric adverse 
events were solicited in a semi-structured neuropsychiatric adverse event interview. Adverse events were 
coded according to MedDRA; v16.1 (http://www.meddra.org/). 
Participants were counted once per row but could be counted in multiple rows.  
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<<FIGURES ADDED HERE FOR DATA VERIFICATION AND APPROVAL PURPOSES 
ONLY.REMOVE BEFORE RESUBMISSION>> 
Figure 1 
 
 
Figure 2 
New data in the adjacent box to 
the left only.  
Source: Fig 1 new data.msg 
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SUPPLEMENTAL MATERIAL 
Study Design 
 
*Varenicline up-titration: 0.5 mg QD for 3 days, 0.5 mg BID for 4 days, then 1 mg BID 
for the following 23 weeks. Abbreviations: BL = baseline; T = telephone contact; V = 
visit in clinic. 
 
 
 
